35 results
6-K
EX-99.1
PBM
Psyence Biomedical Ltd. Warrant
20 Sep 24
Share Purchase and Sale Agreement
5:00pm
and expressions bear the meanings assigned to them and cognate expressions bear corresponding meanings –
"Due Diligence Investigation" means the due diligence … that it, in its sole discretion, is satisfied the outcome of the Due Diligence Investigation.
Unless all the Conditions Precedent have been fulfilled
424B3
PBM
Psyence Biomedical Ltd. Warrant
30 Aug 24
Prospectus supplement
4:00pm
, in Australia. As stated above, Filament’s PEX010 will serve as the product candidate under investigation during the Phase IIb Study.
Psyence’s R&D … as the product candidate under investigation during the Phase IIb Study.
Psyence’s R&D capabilities
Psyence’s CEO (Dr. Neil Maresky) and Medical Director
F-1
EX-5.1
PBM
Psyence Biomedical Ltd. Warrant
19 Aug 24
Registration statement (foreign)
4:07pm
contemplated hereby.
We have not undertaken any independent investigation to verify the accuracy of any of the foregoing assumptions.
When our opinion
F-1
PBM
Psyence Biomedical Ltd. Warrant
19 Aug 24
Registration statement (foreign)
4:07pm
investigation during the Phase IIb Study.
Psyence’s R&D capabilities
Psyence’s CEO (Dr. Neil Maresky) and Medical Director (Dr. Clive Ward-Able) are both … PEX010 will serve as the product candidate under investigation during the Phase IIb Study.
Psyence’s R&D capabilities
Psyence’s CEO (Dr. Neil Maresky
424B3
PBM
Psyence Biomedical Ltd. Warrant
19 Aug 24
Prospectus supplement
9:27am
investigation during the Phase IIb Study.
Psyence’s R&D capabilities
Psyence’s CEO (Dr. Neil Maresky) and Medical Director (Dr. Clive Ward-Able) are both … as the product candidate under investigation during the Phase IIb Study.
Psyence’s R&D capabilities
Psyence’s CEO (Dr. Neil Maresky) and Medical Director (Dr
POS AM
4qebls0e
12 Aug 24
Prospectus update (post-effective amendment)
5:23pm
6-K
EX-99.1
ljpf8sg5jm
31 Jul 24
Common Stock Purchase Agreement
4:11pm
6-K
EX-99.2
o94rnpt1u4a6j1
31 Jul 24
Common Stock Purchase Agreement
4:11pm
S-8
EX-5.1
yfg7lfdjc6
30 Jul 24
Registration of securities for employees
5:38pm
6-K
EX-4.2
mvy pozqkyf2
23 Jul 24
Current report (foreign)
4:05pm
6-K
EX-4.2
zwvlb
20 Jun 24
Current report (foreign)
4:10pm
6-K
EX-4.2
t9y9ou492666boa4z408
6 Jun 24
Current report (foreign)
8:00am
F-1/A
hd2m90km
6 May 24
Registration statement (foreign) (amended)
8:27pm
F-1/A
6rrv0nbrc9by1j9
18 Apr 24
Registration statement (foreign) (amended)
6:03am
F-1/A
EX-5.1
4h6e hmy0t04
18 Apr 24
Registration statement (foreign) (amended)
6:03am
F-1/A
EX-10.17
1jmo7b5o
18 Apr 24
Registration statement (foreign) (amended)
6:03am
F-1
EX-5.1
lw6bvlplre
9 Feb 24
Registration statement (foreign)
4:09pm
F-1
xlc9ibp
9 Feb 24
Registration statement (foreign)
4:09pm
20-F
EX-4.9
jcyhxb
31 Jan 24
Annual report (foreign)
5:05pm